指南与共识产科母胎医学

预防早产和管理早产的新药专家共识:目标产品概况

Expert consensus on novel medicines to prevent preterm birth and manage preterm labour: Target product profiles.
指南 / 共识 · BJOG · 2022-10-27

该共识通过文献回顾、在线国际调查和深度访谈,汇集全球利益相关者对预防早产和管理早产新药的目标产品概况(TPP)意见。访谈显示对室温稳定性、无需额外药物特异性临床监测及中低收入国家可负担性为最低可接受要求有强烈共识;调查中每个TPP仅一个变量未达共识(25%不同意或强烈不同意)。

要点

  • 新药最低可接受要求包括室温稳定性、无需额外药物特异性临床监测及中低收入国家可负担性。
  • 每个TPP仅一个变量未达共识(25%不同意或强烈不同意)。
  • TPP为评估新候选药物及在不同场景实施的潜力提供指导。

核心结论

  • 早产领域对预防早产和管理早产新药应具备的特征有强烈共识,TPP为评估新候选药物及其实施潜力提供必要指导。

研究设计与样本

  • 混合方法研究,包括文献回顾、在线国际调查和深度访谈,对象为全球早产/分娩及药物开发领域利益相关者。
  • 共进行21次访谈;调查受访者包括临床医生、研究人员、资助机构人员、国际公共组织人员、项目实施者、政策制定者、消费者倡导组织代表等。

主要发现

  • 访谈参与者对室温稳定性、无需额外药物特异性临床监测及中低收入国家可负担性作为最低可接受要求有强烈共识。
  • 调查结果显示利益相关者强烈共识,每个TPP仅一个变量未达共识(25%不同意或强烈不同意)。

关键数值与推荐

  • 新药最低可接受要求包括室温稳定性、无需额外药物特异性临床监测及中低收入国家可负担性。
  • 每个TPP仅一个变量未达共识(25%不同意或强烈不同意)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop target product profiles (TPPs) for new medicines for preterm birth prevention and preterm labour management that address the real-world need of women and healthcare providers, informed by views and agreement amongst globally diverse stakeholders. DESIGN: Mixed methods. SETTING: Global (with a focus on low- and middle-income countries, LMICs). SAMPLE: Global stakeholders with diverse expertise in preterm labour/birth and drug development. METHODS: Following an initial literature review, diverse stakeholders were invited to participate in an online international survey and in-depth interviews. The level of stakeholder agreement with TPPs was assessed, and findings from interviews were synthesised to inform the final TPPs. MAIN OUTCOMES MEASURES: Level of stakeholder agreement on the minimum and preferred requirements for preterm labour/birth medicines. RESULTS: We performed 21 interviews. Interview participants demonstrated strong agreement on room temperature stability, no additional drug-specific clinical monitoring, and affordability in LMICs being the minimal acceptable requirements. Points of discussion were raised around the target population. Survey respondents included clinicians, researchers, funding agency staff, international public organisation staff, programme implementers, policymakers, representatives of consumer advocacy organisations and other relevant stakeholders from maternal health systems. Survey results indicated strong agreement amongst stakeholders, with only one variable in each TPP not reaching consensus (i.e. 25% disagree or strongly disagree). CONCLUSIONS: There is strong consensus within the preterm labour/birth community on the characteristics that new medicines for preterm birth prevention and preterm labour management must achieve. These TPPs provide necessary guidance to evaluate new candidates and their potential for implementation in a range of settings.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. McDougall ARA, Tuttle A, Goldstein M, et al. Expert consensus on novel medicines to prevent preterm birth and manage preterm labour: Target product profiles. BJOG. 2022. PMID: 36209501. doi:10.1111/1471-0528.17314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。